您当前的位置：
首页 >
文章列表页 >
Cost-effectiveness analysis of insulin degludec and insulin aspart in Chinese patients with type 2 diabetes mellitus
更新时间：2025-11-25

    • Cost-effectiveness analysis of insulin degludec and insulin aspart in Chinese patients with type 2 diabetes mellitus

    • “According to the latest research, Chinese patients with type 2 diabetes can increase health output and reduce medical costs by using Degu Aspartan dual insulin therapy.”
    • ZHONGGUO YAOFANG   Vol. 36, Issue 22, Pages: 2809-2814(2025)

    • DOI：10.6039/j.issn.1001-0408.2025.22.10    

      CLC： R956;R977.1+5

    • Received：22 July 2025，

      Revised：2025-10-31，

      Accepted：03 November 2025，

      Published：30 November 2025

    移动端阅览

  • QIN Jiali,ZHANG Yawen,ZHANG Lei,et al.Cost-effectiveness analysis of insulin degludec and insulin aspart in Chinese patients with type 2 diabetes mellitus[J].ZHONGGUO YAOFANG,2025,36(22):2809-2814. DOI： 10.6039/j.issn.1001-0408.2025.22.10.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

No data

Related Author

No data

Related Institution

No data
0